<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04731610</url>
  </required_header>
  <id_info>
    <org_study_id>IC 2020-09</org_study_id>
    <nct_id>NCT04731610</nct_id>
  </id_info>
  <brief_title>Randomized, Multicenter, Phase III Trial to Assess Conformal Post-operative Radiotherapy vs. Surveillance After Complete Resection of Stage II/III Thymoma</brief_title>
  <acronym>RADIO-RYTHMIC</acronym>
  <official_title>Randomized, Multicenter, Phase III Trial to Assess Conformal Post-operative Radiotherapy vs. Surveillance After Complete Resection of Stage II/III Thymoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Curie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Curie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study : to compare the Recurrence-Free survival (RFS) between&#xD;
      arms. RFS is defined as time from randomisation to the first recurrence (either&#xD;
      local-regional or distant) or death of any cause.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2, 2021</start_date>
  <completion_date type="Anticipated">March 1, 2029</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence-Free survival (RFS)</measure>
    <time_frame>3 years</time_frame>
    <description>to compare the Recurrence-Free survival (RFS) between arms. RFS is defined as time from randomisation to the first recurrence (either local-regional or distant) or death of any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Local-regional (pleural or pericardial) recurrence</measure>
    <time_frame>3 years</time_frame>
    <description>Local-regional (pleural or pericardial) recurrence; location of recurrence /removed</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">314</enrollment>
  <condition>Thymoma Malignant Recurrent</condition>
  <arm_group>
    <arm_group_label>Post-operative radiotherapy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Tumour resection followed by radiotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Surveillance after tumour resection</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Tumour resection</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>postoperative radiotherapy after complete resection of thymoma</description>
    <arm_group_label>Post-operative radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Surveillance after resection</intervention_name>
    <description>Surveillance after tumour resection</description>
    <arm_group_label>Surveillance after tumour resection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 18 &lt; Age &lt; 75 years old&#xD;
&#xD;
          2. ECOG performance status ≤1&#xD;
&#xD;
          3. Preoperative chemotherapy is allowed. Maximum of 4 cycles are authorized. Surgery&#xD;
             should be realized ≤ 2 months after the last chemotherapy injection.&#xD;
&#xD;
          4. Histologically diagnosed thymoma at pathological examination of surgical specimen&#xD;
             after pathological review; for note, centralized, real-time, systematic pathological&#xD;
             review is standard through the RYTHMIC network in France&#xD;
&#xD;
          5. Complete resection at pathological examination of the surgical specimen after surgery&#xD;
             conducted through standard, recommended approach ensuring accurate assessment of&#xD;
             resection status&#xD;
&#xD;
          6. Stage IIb or III disease according to the Masaoka-Koga staging system; this&#xD;
             corresponds to stage pT1a with capsule invasion, until stage pT3 N0 M0 in the 8th TNM&#xD;
             staging system TNM UICC/AJCC&#xD;
&#xD;
          7. Availability of thoracic Computed-Tomography (CT) scan with IV contrast (in the&#xD;
             absence of contra-indications) performed before treatment&#xD;
&#xD;
          8. Availability of a thoracic Computed-Tomography (CT) scan with IV contrast showing&#xD;
             absence of residual disease after surgical resection of the tumor&#xD;
&#xD;
          9. Pulmonary function tests after surgery with FEV1 &gt; 1L or ≥ 35% of the theoretical&#xD;
             value and DLCO ≥ 40%&#xD;
&#xD;
         10. Signature of informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - 1. Age &gt; 75 years old 2. Histology of thymic carcinoma 3. Delivery of post-operative&#xD;
        chemotherapy, concurrent chemotherapy to radiotherapy 4. Presence of microscopic or&#xD;
        macroscopic residual tumor after surgery or metastases (R1 or R2 resection) 5.&#xD;
        Uncontrolled, clinically significant pleural or pericardial effusion 6. Patients with prior&#xD;
        radiation therapy to the thorax. Patients treated with conformal radiotherapy for prior&#xD;
        breast or head and neck neoplasms should be discussed with PI 7. Evidence of severe or&#xD;
        uncontrolled systemic disease as judged by the investigator 8. Recent (&lt; 6 months) severe&#xD;
        cardiac disease (uncontrolled arrhythmia, congestive heart failure, infarction, pace-maker)&#xD;
        or pulmonary disease. Controlled and non clinically symptomatic arrhythmia is allowed.&#xD;
&#xD;
        9. Current or past history of neoplasm diagnosed within the last 3 years, except: basal&#xD;
        cell carcinoma of the skin, in situ carcinoma of the cervix, and bladder in situ. A patient&#xD;
        diagnosed for another neoplasm 3 years ago or more, treated and considered as cured may be&#xD;
        included in the study if all the other criteria are respected 10. Pregnancy or breast&#xD;
        feeding or inadequate contraceptive measures for women of childbearing potential during&#xD;
        PORT 11. Patients who, for family, social, geographic or psychological reasons, cannot be&#xD;
        adequately followed up and/or are incapable of undergoing regular controls, 12. Patients&#xD;
        deprived of freedom or under guardianship&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Francis NYASSE</last_name>
    <phone>(0) 1.47.11.18. 91</phone>
    <phone_ext>33</phone_ext>
    <email>gilles.nyassemessene@curie.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institut de Cancérologie de l'Ouest Angers</name>
      <address>
        <city>Angers</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>François THILLAYS, MD</last_name>
    </contact>
    <investigator>
      <last_name>François MORDANT, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Caen</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Youssef OULKHOUIR, MD</last_name>
    </contact>
    <investigator>
      <last_name>Youssef OULKHOUIR, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CLCC François BACLESSE</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Delphine LEROUGE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Delphine LEROUGE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CLCC Georges François Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Etienne MARTIN, MD</last_name>
    </contact>
    <investigator>
      <last_name>Etienne MARTIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Florence LE TINIER, MD</last_name>
    </contact>
    <investigator>
      <last_name>Florence LE TINIER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Lyon</name>
      <address>
        <city>Lyon</city>
        <zip>69002</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Marylise GINOUX, MD</last_name>
    </contact>
    <investigator>
      <last_name>Marylise GINOUX, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>La Timone AP-HM</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Pascal THOMAS, Pr</last_name>
    </contact>
    <investigator>
      <last_name>Pascal THOMAS, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut du Cancer de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34090</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Xavier QUENTIN, Pr</last_name>
    </contact>
    <investigator>
      <last_name>Xavier QUENTIN, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Nicolas GIRARD, PR</last_name>
      <email>nicolas.girard2@curie.fr</email>
    </contact>
    <investigator>
      <last_name>Nicolas GIRARD, PR</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-Louis AP-HP</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Sophie GUILLERM, MD</last_name>
    </contact>
    <investigator>
      <last_name>Sophie GUILLERM, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Bichat AP-HP</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Pierre MORDANT, Pr</last_name>
    </contact>
    <investigator>
      <last_name>Pierre MORDANT, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Rennes Hôpital Sud</name>
      <address>
        <city>Rennes</city>
        <zip>35056</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Mallorie KERJOUAN, MD</last_name>
    </contact>
    <investigator>
      <last_name>Mallorie KERJOUAN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Pierre-Emmanuel FALCOZ, Pr</last_name>
    </contact>
    <investigator>
      <last_name>Pierre-Emmanuel FALCOZ, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31300</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Jonathan KHALIFA, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jonathan KHALIFA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Eric PICHON, MD</last_name>
    </contact>
    <investigator>
      <last_name>Eric PICHON, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de Lorraine Nancy</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <zip>54519</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Christelle CLEMENT-DUCHENE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Christelle CLEMENT-DUCHENE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Angela BOTTICELLA, MD</last_name>
    </contact>
    <investigator>
      <last_name>Angela BOTTICELLA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>January 26, 2021</study_first_submitted>
  <study_first_submitted_qc>January 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 1, 2021</study_first_posted>
  <last_update_submitted>July 1, 2021</last_update_submitted>
  <last_update_submitted_qc>July 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thymoma</mesh_term>
    <mesh_term>Thymus Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

